Paper Details
- Home
- Paper Details
Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study.
Author: AmatoGiorgio, AndraccoRomina, ArianiAlarico, ArrigoniEugenio, BeccioliniAndrea, BernardiSimone, BraviElena, BruzzeseVincenzo, CaccavaleRosalba, ColinaMatteo, Dal BoscoYlenia, De LuciaFrancesco, Del MedicoPatrizia, Di DonatoEleonora, DittoMaria Chiara, FarinaAntonella, FerreroGiulio, FotiRosario, FranchinaVeronica, FusaroEnrico, GirelliFrancesco, IannielloAurora, Lo GulloAlberto, LucchiniGianluca, LumettiFederica, MansuetoNatalia, MarchettaAntonio, Molica ColellaAldo Biagio, Molica ColellaFrancesco, NuceraValeria, ParisiSimone, ParoliMarino, PlatéIlaria, SalvaraniCarlo, SandriGilda, SantilliDaniele, ScolieriPalma, VisalliElisa, VolpeAlessandro
Original Abstract of the Article :
INTRODUCTION: Enthesitis and dactylitis are difficult-to-treat features of psoriatic arthritis (PsA), leading to disability and affecting quality of life. OBJECTIVE: The aim of this study is to evaluate enthesitis (using the Leed enthesitis index (LEI)) and dactylitis at 6 and 12 months in patients...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299365/
データ提供：米国国立医学図書館（NLM）
Apremilast: A Beacon of Hope for Enthesitis and Dactylitis in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease that can cause significant pain and disability. This study investigates the effectiveness of apremilast, a medication that targets inflammation, in treating enthesitis and dactylitis, two debilitating symptoms of PsA. The researchers analyzed data from a multicenter study involving patients with PsA who were treated with apremilast. Their findings provide encouraging evidence for the efficacy of apremilast in managing these challenging conditions.
A New Weapon in the Fight Against Psoriatic Arthritis
The study demonstrates that apremilast can effectively reduce enthesitis and dactylitis activity in patients with PsA. This finding offers a promising new treatment option for individuals with this debilitating condition. It's a ray of hope in the desert of PsA, offering a potential path to relief and improved quality of life.
Living with Psoriatic Arthritis: Managing the Challenges
PsA can present significant challenges, affecting both physical well-being and quality of life. This study highlights the importance of finding effective treatments to manage the disease and its debilitating symptoms. It encourages individuals with PsA to work closely with their healthcare providers to develop a personalized treatment plan that meets their individual needs. It's a reminder that while PsA can be challenging, there are resources and treatments available to help us navigate the journey and find a path to better health.
Dr.Camel's Conclusion
This study offers hope for individuals living with PsA, particularly those struggling with enthesitis and dactylitis. Apremilast has emerged as a potential treatment option, offering a glimmer of hope in the desert of chronic inflammation. By embracing innovative approaches, we can work towards a future where PsA is managed effectively and patients can live healthier and more fulfilling lives.
Date :
- Date Completed n.d.
- Date Revised 2023-07-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.